Multi-infarct Dementia Market Size, Share & Trends Report

Multi-infarct Dementia Market Size, Share & Trends Analysis Report By Treatment, Regional Outlook, Competitive Strategies, And Segment Forecasts, 2019 To 2025

  • Published Date: ---
  • Base Year for Estimate: ---
  • Report ID: GVR1505
  • Format: Electronic (PDF)
  • Historical Data: ---
  • Number of Pages: 0

The global multi-infarct dementia market is expected to witness growth owing to the rising prevalence of strokes and blockage in brain nerves.  The multi infarct dementia is a series of minor brain strokes which results in the disruption of blood flow in the brain. It is also termed as vascular dementia (VaD). According to National Institute of Health, the second largest form of dementia is multi infarct dementia, which accounts for the maximum cases of people who are above the age of 65. Thus, increasing geriatric population base worldwide is also propelling the global multi infarct dementia market. Various technological advancements in several inhibitors used for the prevention of dementia is another notable factor expected to further fuel the global multi infarct dementia market over the forecast period. However, unavailability of treatment for reversing the brain cell damage due to stroke along with the primary focus of therapy on prevention and control of future strokes, is expected to restrain the growth of the multi infarct dementia market over next few years.

The entire multi-infarct dementia market on the basis of treatment is segmented into pharmacological and non pharmacological treatment. The pharmacological treatment for dementia includes cholinesterase inhibitors such as rivastigmine, galantamine and donepezil. Revastigmine inhibitor has the capacity to inhibit both butyrylcholinesterase and acetylcholinesterase. It is termed as second generation cholinesterase inhibitor. Other pharmacological medications include Cytidine 5’-Diphosphocholine, folic acid, hydergine, nimodipine and memantine. Other drugs used for the treatment of multi infarct dementia are angiotensin converting enzyme inhibitors (ACE inhibitors), calcium channel blockers (CCBs) and selective serotonin reuptake inhibitors (SSRIs). Non pharmacological treatment segment is expected to witness low growth over next few years due to the low prognosis and survival rate of patients.

Geographically, the overall multi-infarct dementia market is segmented into North America, Asia Pacific, Europe, Latin America and MEA. As of 2014, North America held largest market share in terms of revenue owing to the increasing incidences of multi infarct dementia coupled with increasing geariatric population base. European market displayed similar traits and followed North American multi infarct dementia market. Asia Pacific is expected to grow at a high pace due to increasing awareness about prevention of brain strokes in this region. Japan owing to increased geriatric base represents approximately  more than 50% of the dementia cases in Asia Pacific. The developed nations such as Japan, Canada, France, Germany and U.S. are anticipated to witness favorable growth over the forecast period.

Various players in the multi-infarct dementia market are adopting several competitive strategies such as collaborations, expansions and acquisitions to keep a strong foothold and gain advantage in the market. Some major players in the market include Forest Laboratories, Inc., Janssen Pharmaceuticals, Inc., Novartis Pharmaceutical Corporation, Pfizer, Inc. and Eisai, Inc.

Pricing & Purchase Options

Buy Chapters or Sections

Avail customized purchase options to meet your exact research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities

Why Choose Us

  • Research support

    24/5 Research support

    Get your queries resolved from an industry expert.

  • Custom research service

    Custom research service

    Design an exclusive study to serve your research needs.

  • Quality assurance

    Quality assurance

    A testimonial for service in the form of BBB "A" Accreditation.

  • BBB Rating dandb
  • Information security

    Information security

    Your personal and confidential information is safe and secure.

  • grand view research PCI DSS complaint grand view research paypal verified